136 related articles for article (PubMed ID: 27112938)
1. Targeted cancer therapy: interactions with other medicines.
Conde-Estévez D
Clin Transl Oncol; 2017 Jan; 19(1):21-30. PubMed ID: 27112938
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
4. Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study.
Stoll P; Kopittke L
Int J Clin Pharm; 2015 Jun; 37(3):475-84. PubMed ID: 25711852
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.
Smelick GS; Heffron TP; Chu L; Dean B; West DA; Duvall SL; Lum BL; Budha N; Holden SN; Benet LZ; Frymoyer A; Dresser MJ; Ware JA
Mol Pharm; 2013 Nov; 10(11):4055-62. PubMed ID: 24044612
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
Keller KL; Franquiz MJ; Duffy AP; Trovato JA
J Oncol Pharm Pract; 2018 Mar; 24(2):110-115. PubMed ID: 27941080
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
[TBL] [Abstract][Full Text] [Related]
10. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?
Budha NR; Frymoyer A; Smelick GS; Jin JY; Yago MR; Dresser MJ; Holden SN; Benet LZ; Ware JA
Clin Pharmacol Ther; 2012 Aug; 92(2):203-13. PubMed ID: 22739140
[TBL] [Abstract][Full Text] [Related]
11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
Veerman GDM; Hussaarts KGAM; Jansman FGA; Koolen SWL; van Leeuwen RWF; Mathijssen RHJ
Lancet Oncol; 2020 May; 21(5):e265-e279. PubMed ID: 32359502
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
14. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
15. Potential drug interactions and duplicate prescriptions among cancer patients.
Riechelmann RP; Tannock IF; Wang L; Saad ED; Taback NA; Krzyzanowska MK
J Natl Cancer Inst; 2007 Apr; 99(8):592-600. PubMed ID: 17440160
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
17. Interactions between oral antineoplastic agents and concomitant medication: a systematic review.
Carcelero E; Anglada H; Tuset M; Creus N
Expert Opin Drug Saf; 2013 May; 12(3):403-20. PubMed ID: 23586848
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy.
Marcath LA; Finley CM; Wong SF; Hertz DL
BMC Cancer; 2021 Mar; 21(1):324. PubMed ID: 33771105
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interactions in pediatric oncology patients.
Balk TE; van der Sijs IH; van Gelder T; Janssen JJB; van der Sluis IM; van Leeuwen RWF; Engels FK
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28205376
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
